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Abstract
Background: The purpose of this pilot study was to evaluate and refine an adjuvant system of color-specific
symbols that are added to medication bottles and to assess whether this system would increase the ability of
patients 65 years of age or older in matching their medication to the indication for which it was prescribed.
Methods: This study was conducted in two phases, consisting of three focus groups of patients from a family
medicine clinic (n = 25) and a pre-post medication identification test in a second group of patient participants
(n = 100). Results of focus group discussions were used to refine the medication label symbols according to
themes and messages identified through qualitative triangulation mechanisms and data analysis techniques.
A pre-post medication identification test was conducted in the second phase of the study to assess
differences between standard labeling alone and the addition of the refined color-specific symbols. The pre-
post test examined the impact of the added labels on participants’ ability to accurately match their
medication to the indication for which it was prescribed when placed in front of participants and then at a
distance of two feet.
Results: Participants appreciated the addition of a visual aid on existing medication labels because it would not be
necessary to learn a completely new system of labeling, and generally found the colors and symbols used in the
proposed labeling system easy to understand and relevant. Concerns were raised about space constraints on
medication bottles, having too much information on the bottle, and having to remember what the colors meant.
Symbols and colors were modified if they were found unclear or inappropriate by focus group participants. Pre-
post medication identification test results in a second set of participants demonstrated that the addition of the
symbol label significantly improved the ability of participants to match their medication to the appropriate medical
indication at a distance of two feet (p < 0.001) and approached significant improvement when placed directly in
front of participants (p = 0.07).
Conclusions: The proposed medication symbol label system provides a promising adjunct to national efforts in
addressing the issue of medication misuse in the home through the improvement of medication labeling. Further
research is necessary to determine the effectiveness of the labeling system in real-world settings.
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Medication misuse is a high-priority topic with conse-
quences that result in adverse drug events (ADEs). The
Institute of Medicine projects that approximately 1.5
million preventable ADEs occur annually and create a
financial burden of approximately $3.5 billion per year
in the United States [1]. Among Medicare enrollees 65
years of age and older, the cost of ADEs in ambulatory
settings is more than $2 billion, of which $887 million
are due to preventable ADEs [2]. The Institute of Medi-
cine estimates that about 530,000 ADEs occur annually
among outpatient Medicare patients over the age of 65
and can be a result of forgetting to take medications,
taking the wrong quantity, and taking the wrong medi-
cation, among other medication adherence related issues
[3,4]. Efforts to improve medication safety and delivery
have been more readily implemented within hospital
and health systems with interventions focused at the
practitioner, pharmacy, and nursing staff level [5]. With
2.7 to 3.6 billion outpatient prescriptions dispensed each
year, it is critical to develop more focused interventions
in the home setting, where the patient is primarily
responsible for medication comprehension and adher-
ence [6,7].
Studies have shown that older patients, patients with
low health literacy, and those who take multiple medica-
tions may have difficulty comprehending medication
labels [8-10]. In any given week, 81% of adults take at
least one medication with 27% of them consuming at
least five different medications [11]. Women over the
age of 65 have the highest rate of medication use, with
94% using at least one medication and 57% using five or
more. Older patients may also read and comprehend
medication labels differently compared to younger popu-
lations in terms of reading speed and error rates accord-
ing to font type [12]. Older adults are particularly
vulnerable to experience adverse health outcomes
related to medication adherence and comprehension
due to higher rates of medication use and lower health
literacy than the general U.S. population [13,14].
Important, but limited, measures have been imple-
mented to address medication and patient safety in the
home, which include improved and standardized medi-
cation labels with clear text, larger font, warning labels,
electronic reminder systems and pill boxes [15-17]. A
White Paper published by the American College of Phy-
sicians Foundation provided a comprehensive review
and action plan on patient safety as it pertains to medi-
cation bottle labels [18]. One recommendation provided
by the White Paper is a need for a symbol system to be
incorporated onto medication bottles. The focus of this
pilot study was to evaluate and refine such a system of
symbols to place on medication bottles and to assess
whether this system would increase the accuracy with
which patients 65 years of age or older could match
their medication to the indication for which it was
prescribed.
Methods
Development of the Tachygraphic Color Organized
Medication System (TCOM)
The TCOM system, also referred to as the medical sym-
bol label system, was conceptualized and developed by
researchers at the Primary Care Research Center/Texas
Prevention Institute at the University of North Texas
Health Science Center at Fort Worth, Texas (UNTHSC).
Researchers developed an easily recognizable image (i.e.
symbol) and corresponding color for each anatomical
main group of the Anatomical Therapeutic Chemical
(ATC) classification system recognized by the World
Health Organization [19]. The heart symbol and the
color red, for example, were used for cardiovascular
agents. Some of the 14 main classes were further subdi-
vided (Figure 1). For example, separate labels were cre-
ated for eye and ear disorders rather than a single label
for sensory disorders. This was developed and refined
with input and expertise from the medical arts staff of
the Informational Technology department at UNTHSC.
The labels consist of a series of repeated colored images
on a 3/4 inch adhesive strip that can be attached below
a standard medication bottle label (Figure 2). Each
colored medication symbol strip represents one of 19
common medication indications.
Study population
The study was conducted in two phases: three focus
groups and a pre-post medication identification test.
Participants for both phases of the study were recruited
from a member clinic of the North Texas Primary Care
Practice-Based Research Network (NorTex). NorTex
consists of a network of over 130 clinics in the North
Texas region and includes primary care clinics focused
on family medicine, general internal medicine, pedia-
trics, geriatrics, and obstetrics/gynecology. A conveni-
ence sample was recruited from a family medicine clinic
by a coordinator working with clinic staff and physi-
cians. Eligible participants were approached either in the
waiting room or immediately after their clinical visit
with the physician. During Phase I, participants were
scheduled for one of the three focus groups that best
met their availability and were consented at the time of
the focus group meeting. For Phase II, interested partici-
pants were either immediately consented and sent to
complete study procedures following their medical visit
or were scheduled for a research visit at the NorTex
research offices.
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pants each, for a total of 25 participants during the first
phase of the study. A separate cohort of 100 participants
took part in the pre-post medication identification test
portion of the study, Phase II. For both phases, partici-
pants were eligible for the study if they were 65 years of
age or older and took a minimum of five long-term pre-
scription medications in at least three different
Indication Color Symbol Sample
Allergic Disorders Orange Person Sneezing
Cardiovascular System Red Heart
Central Nervous System Gray Brain
Dermatological Disorders Beige Hand/Skin
Ear Disorders Black/White Ear
Endocrine System/Metabolic Fuchsia Candy Cane
Eye Disorders/Ophthalmology Indigo Eye
Gastrointestinal Tract Brown Toilet
Immune System/Vaccines Purple Syringe & Needle
Infections & Infestations Lime Green Bug
Musculoskeletal Disorders Black/White Bones
Neoplasms/Oncology Teal IV Bag & Line
Nutrition Green Apple
Ob/Gyn Pink Female
Pain & Pyrexia Red Stick-figure man, 
bent forward 
Poisoning & Drug Dependence Orange No Smoking Sign
Respiratory Tract Light Blue Lungs
Urogenital System Yellow Water
Sleep Aides/Hypnotics Black ZZZZZ
Figure 1 TCOM medication label system.
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excluded from participating based on the visual nature
of the study. All study participants were English speak-
ing. Study procedures were approved by the UNTHSC
Institutional Review Board.
Study Procedures
Focus groups were used to provide feedback on the pre-
liminary medication symbol system for 19 medication
indications [20]. A trained facilitator conducted focus
groups using a developed focus group moderator guide.
Focus groups took place at the Primary Care Research
Center at the University of North Texas Health Science
Center, and each participant was reimbursed $30 for
their time and effort. Each focus group lasted approxi-
mately 90 minutes, and the conversations were docu-
mented through digital audio recording and note taking.
A trained individual transcribed all audio recordings.
Focus group results were used to modify the medication
labeling system according to participant recommenda-
tions which were implemented prior to the second
phase of the study.
A pre-post medication identification test was con-
ducted in Phase II to assess differences between stan-
dard medication bottle labeling alone and the addition
of the TCOM medication label symbols in terms of
participants’ ability to accurately match their prescribed
medication to the correct indication. Participants were
asked to bring all of their medications, including over-
the-counter products, to the study visit. Each participant
was asked a series of questions related to identifying
each medication, its associated dosage, and the medical
conditions for which their medications were prescribed.
Participants were then asked to match their medication
bottles with the appropriate medical condition. A
TCOM label for the corresponding medical indication
was then added to the bottom of each bottle below the
existing pharmacy medication label, and the participant
was again asked to match each bottle with the appropri-
ate medical condition. This procedure was repeated
f r o mad i s t a n c eo ft w of e e t ,r e p r e s e n t i n gt h ed i s t a n c e
needed to identify a medication bottle from common
medication storage locations such as kitchen counters,
medicine cabinets, cupboards or dressers. Each study
visit took approximately 30 minutes, and participants
were reimbursed $20 for their time and effort.
Qualitative measures and analysis
Focus group data were analyzed using thematic content
analysis. Data were collated on knowledge of the pur-
pose of medication labeling, barriers in current labeling
systems, initial thoughtso nt h eT C O Ms y s t e m ,a n d
Figure 2 TCOM sample bottles.
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The responses to each question were compiled for a
total of 25 participants for the three focus groups.
Themes or codes were then derived from all of the
responses to each question. These qualitative results
were then used to modify and refine the proposed label-
ing system prior to the commencement of the second
phase of the study.
Quantitative measures and analysis
During the Phase II pre-post medication identification
test, data were collected on the number of medications
a participant was taking, the number of medications the
participant could correctly match with its prescribed
indication before the label was added, the number of
medications a participant could correctly match with its
prescribed indication after the label was added, and the
number of medications the participant could correctly
match with its prescribed indication two feet away from
the medication bottles pre and post labeling.
A power analysis was conducted for Phase II of the
study based on 100 participants. Using a paired samples
t-test and alpha of 0.05, a sample size of 100 allowed
greater than 80% power to detect a difference. Calcula-
tions assumed participants would incorrectly identify at
least one medication in the pre-measurement and would
correctly identify all medications in the post-measure-
ment. Since a minimum of five medications was
required for inclusion in the study, this constituted a
20% difference.
The number of medications a participant identified
correctly out of total medications was converted to a
percent correct, or score, for both the pre- and post-
measurements. Due to a non-normal distribution and
the paired association of pre and post scores, a Wil-
coxon Signed Ranks Test was performed to examine dif-
ferences between pre and post scores for identifying the
medication bottles while in front of the person and at
two feet away. Differences were considered statistically
significant with a two-tailed probability of 0.05 or less.
Results
Phase I results
When asked about knowledge of medication labels,
focus group participants commonly identified informa-
tion and instructions found on standard labels such as
when to take medicine, frequency, and strength of medi-
cation. Participants expressed that additional informa-
tion is needed on current medication labels such as the
purpose of the medication, and the color/size of pills.
They indicated that the writing was typically too small
to read, too much information was placed on the label,
and that color coding would be helpful unless someone
was color-blind. Participants stated that clear
instructions on medication schedule and dosage, larger
type, and bold letters were needed, especially for those
who were visually-impaired. Similarities in size or color
of different medications and change by manufacturers in
size or color of pills were identified as barriers to medi-
cation recognition. Participants also stated that medica-
tions could be confusing to identify if they were similar
in appearance to other medications, name-brand versus
generic, or contained unclear, inadequate instructions.
Medication cost also emerged as a theme and important
concern for participants. Participants reported that Med-
icare only covers generic medications, forcing patients to
shop around to try to find the best price, and some indi-
viduals split pills to save money.
Participants stated that a new symbol label system
would be beneficial and appreciated the idea of an addi-
tional aid incorporated with existing medication labels
because it would not be necessary to learn a completely
new system of labeling. Participants generally found that
the colors and symbols used in the proposed labeling
system were easy to understand, relevant, and “self-
explanatory.” They noted that colors and symbols were
useful for both English and non-English speakers, and
found certain colors such as black for sleep aids or blue
for respiratory medications particularly relevant.
Concerns were raised about having too much informa-
tion on the bottle, not having enough space for the
TCOM label in addition to existing labeling, and having
to remember what colors meant. Participants stated that
some colors were inappropriate and unclear in relation
to the associated indication, and some symbols were
confusing and unfamiliar. Participant concerns and sug-
gestions were then used to revise the labeling system.
For example, the color red was incorporated into the
symbol for pain and pyrexia because participants asso-
ciated the color red more closely with pain than the ori-
ginal purple color used in the symbol. Participants also
suggested that colors should be bright and should be
placed either at the bottom of the bottle or added to
printed inserts on side effects.
Phase II results
Table 1 provides the demographic characteristics of the
100 participants of Phase II. One participant did not
complete the post label questions; therefore, that partici-
pant is excluded from the paired analysis. The partici-
pants were 56% male, 82% white, and 67% had more
than a high school education. The average age of parti-
cipants was 73.4 years (range 65-88 years). Participants
took an average of 11 different medications (range 5-29)
from 8 different classifications (range 3-17).
Prior to placing the TCOM label on the medication
bottles, 88.6% of the medications were correctly
matched to their prescribed indication when placed in
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cations were identified correctly when placed at a 2-feet
distance. After placing the TCOM label onto medication
bottles, the percent identified correctly significantly
improved when bottles were placed at a 2-feet distance
(88.6%, p < 0.001) and trended toward significance when
placed in front of participants (92.3%, p = 0.07). An
effect size (Cohen’s d) of 0.15 was obtained for medica-
tions placed in front of participants and 0.25 for medi-
cations placed at two feet away.
Discussion
Although institutional and policy level changes have
been implemented to improve medication adherence,
[21-24] less attention has been placed on elderly consu-
mers’ ability to understand medication labels to reduce
medication misuse at home [18]. The development of an
easily implementable tool such as the TCOM labeling
system offers pharmacies and health care providers the
potential to decrease medication errors among adults 65
years of age and older, a population that is more likely
to be on multiple medications and is more vulnerable to
adverse drug events than the general population [25,26].
The TCOM system can empower older adults with an
accessible system to enhance correct use of medications
in the home and potentially decrease adverse events
associated with medication misuse or incorrect use.
Qualitative responses by study participants confirmed
the need for clear label formatting, explicit instructions
on dosage, and supported the idea of adding an easily
identifiable visual aid to existing medication labels [18].
Hwang and colleagues found that commonly used illus-
trations that are currently used on medication labels do
not increase patients’ ability to identify their medica-
tions, and in some cases, may be ambiguous or mislead-
ing [27]. Although further refinement of our TCOM
label system may be necessary to ensure the clarity of
the colors and symbols used, our pilot study implemen-
ted a focus group phase to foster input into the develop-
ment of a set of symbols that would be easily
identifiable by the target population. Pre-post medica-
tion identification test results show that the TCOM
label system did in fact improve patients’ ability to cor-
rectly identify their medications from a distance of two
feet, and approached significance when placed directly
in front of study participants. These results suggest that
the proposed labeling system has the potential to be a
helpful visual addition to current medication bottle
labels, since visual aids currently used on bottle labels
may not be effective.
Although participants were able to more accurately
identify their medications at a distance of two feet after
the addition of the TCOM label, the small effect size
may call into question the clinical relevance of study
results. However, the incorrect use of even one medica-
tion can result in adverse events, including hospitaliza-
tions or deaths, and/or suboptimal treatment of a
medical condition. Therefore, even small improvements
in medication identification have the potential to reduce
the incidence of preventable adverse drug events and
improve medical outcomes. Care must also be taken in
the interpretation of study results due to the small sam-
ple size. Results are specific to patients 65 and older
from a member clinic of the North Texas Primary Care
Practice-Based Research Network and may not be gen-
eralizable to other populations. Recall bias may have
occurred during the implementation of the pre-post test
assessments. Participants may have remembered the
purpose of their medications more clearly after the addi-
tion of the TCOM label since they were asked to recall
the purpose of their medicines prior to the addition of
the label. However, participants were not informed
whether or not they had matched their medication to
the correct indication during the assessment process,
and they were expected to already be familiar with their
medications. Participants were not asked to learn a set
Table 2 Percent of Medication Bottles Identified Correctly
Variable Average Percent Correct p-value*
In front of person pre label 88.5 0.07
In front of person post label 92.3
At two feet distance pre label 81.1 < 0.001
At two feet distance post label 88.6
*Wilcoxon Signed Rank Test
Table 1 Demographic Characteristics of the TCOM
Sample (n = 100)
Variable n (%)
Gender
Male 56 (56.0)
Female 44 (44.0)
Race/Ethnicity
White/Caucasian 82 (82.0)
Black/African American 12 (12.0)
Hispanic 5 (5.0)
Other 1 (1.0)
Highest Grade Completed*
Less than High School 8 (8.0)
High School 24 (24.0)
More than High School 67 (67.0)
Mean (sd)**
Age 73.4 5.6
Number of Medications 11.4 5.1
Number of Medication Classes 7.7 2.9
*Highest grade completed is missing for one respondent.
** sd = standard deviation
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rently taking a minimum of five prescription medica-
tions in at least three medication classes in order to
qualify for the study.
It is difficult to assess the impact of recall bias on
study results due to lack of a comparison group and
randomized study design. To address this issue, further
study is recommended to determine the utility of a
visual system of labeling in real-world settings to assess
the comparative effectiveness of the proposed labeling
system to current bottle labels. Studies have shown that
adults 65 years of age and older have the lowest average
literacy rate among all age groups and that literacy can
h a v eas i g n i f i c a n ti m p a c to nap a t i e n t ’s ability to recog-
nize medications [9,28]. Further study is needed in
home, pharmacy, and community settings to determine
how social factors outside of a research setting impact
the suitability and effectiveness of the TCOM labeling
system.
Conclusions
Pilot study results show a promising addition in efforts
to address medication misuse in the home through the
improvement of medication labeling. Further research is
necessary in order to determine the effectiveness of the
TCOM labeling system in real-world settings.
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